N@N

Micrus Endovascular Receives Approval to Market DeltaPaq and DeltaPlush Microcoils in Japan

^{Published on 2010-06-17 01:20:21 - Market Wire}
 

SAN JOSE, Calif.--([ BUSINESS WIRE ])--Micrus Endovascular Corporation (NASDAQ:MEND) today announced receipt of Shonin approval from the Ministry of Health, Labour and Welfare to market in Japan its novel bare platinum and Cerecyte^® DeltaPaqa" filling and DeltaPlusha" finishing microcoils for the treatment of cerebral aneurysms and treatments in the peripheral vasculature. DeltaPaq and DeltaPlush microcoils feature Micrus Endovasculara™s Delta Winda" technology, which is designed to achieve greater intra-aneurysmal packing density than conventional microcoils. Sales of DeltaPaq and DeltaPlush microcoils in Japan will be managed by Goodman Co., Ltd., Micrus Endovasculara™s exclusive distributor in the Japanese market.

"With Shonin approval for DeltaPaq and DeltaPlush microcoils, we can provide Japanese physicians with access to our exclusive Delta Wind technology, further building on our already significant presence in the rapidly growing Japanese market"

aWith Shonin approval for DeltaPaq and DeltaPlush microcoils, we can provide Japanese physicians with access to our exclusive Delta Wind technology, further building on our already significant presence in the rapidly growing Japanese market,a said John Kilcoyne, Chairman and CEO of Micrus Endovascular. aOur DeltaPaq and DeltaPlush microcoils have been very well received by physicians in the U.S. and Europe and represent a significant portion of our worldwide quarterly revenues. Additionally these microcoils have achieved high reorder rates, and have proven instrumental in opening new accounts and allowing for pull-through opportunities for other Micrus products.a

Micrus Endovasculara™s Delta Wind technology fundamentally changes the shape of the microcoil primary wind, allowing the coil to easily change direction and to find and fill open spaces within the cerebral aneurysm that might be missed by traditional coils. The DeltaPaq microcoil is designed to enable physicians to achieve greater coil packing density, which may reduce the rate of recanalization and the need for re-treatment. The DeltaPlush microcoil incorporates Micrus Endovasculara™s softest platinum wire to provide added flexibility to find and fill gaps, helping to provide superior finishing at the aneurysm neck.

About Micrus Endovascular Corporation

Micrus develops, manufactures and markets implantable and disposable medical devices for use in the treatment of cerebral vascular diseases. Micrus products are used by interventional neuroradiologists, interventional neurologists and endovascularly trained neurosurgeons to treat both cerebral aneurysms responsible for hemorrhagic stroke and intracranial atherosclerosis, which may lead to ischemic stroke. Hemorrhagic and ischemic stroke are both significant causes of death and disability worldwide. The Micrus product lines enable physicians to gain access to the brain in a minimally invasive manner through the vessels of the arterial system. Micrusa™ proprietary, three-dimensional microcoils anatomically deploy within the aneurysm, forming a scaffold that conforms to a wide diversity of aneurysm shapes and sizes. Micrus also sells stents, balloon catheters, access devices such as guide catheters, microcatheters, guidewires and accessory products used in conjunction with its microcoils. For more information, visit [ www.micruscorp.com ].

Forward-Looking Statements

Micrus, from time to time, may discuss forward-looking information, including estimated fiscal year 2010 revenues and profitability. Except for the historical information contained in this release, all forward-looking statements are predictions by the Companya™s management and are subject to various risks and uncertainties that may cause results to differ from managementa™s current expectations. Such factors include the risk of inconclusive or unfavorable clinical trial results, the Companya™s ability to obtain, and the timing of, regulatory approvals and clearances for its products, product enhancements or future products, continued growth in embolic coiling procedures and market acceptance of our products and other risks affecting the Company, including the current worldwide economic conditions, the Companya™s limited operating history and history of significant operating losses, fluctuations in quarterly operating results, which are difficult to predict, currency exchange rate fluctuations, the Companya™s dependence on developing new products or product enhancements, challenges associated with complying with applicable state, federal and international regulations related to sales of medical devices and governing Micrusa™ relationships with physicians and other consultants, the Companya™s ability to compete with large, well-established medical device manufacturers with significant resources and other risks as detailed from time to time in risk factors and other disclosures in the Companya™s Annual Report on Form 10-K for the fiscal year ended March 31, 2010 as well as in its other filings with the Securities and Exchange Commission. All forward-looking statements in this release represent the Companya™s judgment as of the date of this release. The Company disclaims, however, any intention or obligation to update forward-looking statements.